What is mensa
Mensa is the largest and oldest high-IQ society in the world. To qualify for membership, you need to score in the top 2% of the population on a standardized IQ test (roughly 130+ on most scales). It was founded in 1946 in England by Roland Berrill and Lancelot Ware.
Key facts:
- The name comes from the Latin word for "table," symbolizing equality among members (a round-table concept)
- It has over 145,000 members in 100+ countries
- Members join primarily for social connection, intellectual discussion, and access to special interest groups covering hundreds of topics
- Mensa does not take positions on political, social, or religious issues
- There are local chapters, national organizations, and an international body (Mensa International)
- Accepted tests include the Mensa-administered supervised test, or prior scores from tests like the SAT (before 1994), certain IQ tests taken through psychologists, etc.
Mensa is often referenced in popular culture as shorthand for "genius-level intelligence," though members themselves note that IQ measures a narrow range of cognitive ability and membership says nothing about wisdom, creativity, or achievement.
What is mensa in specific toxicity of anti cancer drug
Reading File
Finding Sources
Searching the Web
mesna uroprotective agent anticancer drug toxicity mechanism hemorrhagic cystitis
Reading File
Reading File
Here is a detailed breakdown of Mesna in the context of anticancer drug toxicity:
Mesna (Sodium 2-Mercaptoethane Sulfonate)
What It Is
Mesna is a uroprotective agent - a drug given alongside certain chemotherapy drugs specifically to prevent bladder toxicity. It is NOT an anticancer drug itself; it is a protective adjunct.
Why It Is Needed
The alkylating agents cyclophosphamide and ifosfamide are hepatically activated by the CYP450 system. This produces two key metabolites:
| Metabolite | Effect |
|---|---|
| Phosphoramide mustard | Desired - causes DNA alkylation and kills tumor cells |
| Acrolein | Unwanted - excreted in urine, causes bladder toxicity |
Acrolein is a highly reactive aldehyde that, when concentrated in the urine, causes hemorrhagic cystitis - inflammation of the bladder presenting with:
- Dysuria (painful urination)
- Hematuria (blood in urine)
- Potentially life-threatening bladder hemorrhage
Ifosfamide also generates an additional toxic metabolite, chloroacetaldehyde, contributing to further urothelial and CNS damage.
Mechanism of Mesna's Protection
Mesna contains a free thiol (-SH) group (hence: 2-mercaptoethane sulfonate). In the urine, this thiol group:
- Binds covalently to acrolein and other reactive urotoxic metabolites
- Forms a stable, inert, non-toxic compound
- Prevents acrolein from interacting with the bladder mucosa
This detoxification occurs only in the urinary tract - Mesna does not interfere with the antitumor activity of phosphoramide mustard in tissues.
Dosing Protocol
With Ifosfamide (standard regimen):
- Mesna IV bolus at the same time as ifosfamide = 20% of the ifosfamide dose
- Repeat at 4 hours = another 20% of ifosfamide dose
- Repeat at 8 hours = another 20% of ifosfamide dose
- Total Mesna dose = 60% of the ifosfamide dose
- Alternatively: a single Mesna dose equal to 100% of the ifosfamide dose
Patients should also receive at least 2 L of oral or IV fluid daily alongside Mesna.
With Cyclophosphamide: Used especially at high doses; combined with vigorous IV hydration.
Important Limitations
- Mesna prevents hemorrhagic cystitis but does NOT protect the kidneys from ifosfamide nephrotoxicity (amifostine may offer some renal protection)
- Mesna does not protect against other ifosfamide toxicities: nausea/vomiting, leukopenia, neurotoxicity, hepatotoxicity (VOD)
- CNS toxicity from chloroacetaldehyde (ifosfamide) is managed with methylene blue, not Mesna
Summary Table
| Feature | Detail |
|---|---|
| Full name | Sodium 2-mercaptoethane sulfonate |
| Drug class | Uroprotective agent |
| Used with | Ifosfamide, cyclophosphamide |
| Target toxicity | Hemorrhagic cystitis |
| Mechanism | Thiol group neutralizes acrolein in urine |
| Antitumor effect | None - purely protective |
| Route | Intravenous (IV) |
Sources: - Lippincott Illustrated Reviews: Pharmacology, p. 1243 | Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1368 | Harrison's Principles of Internal Medicine 22E
This is a shared conversation. Sign in to Orris to start your own chat.